Performance of a Multiplex Serological Helicobacter pylori Assay on a Novel Microfluidic Assay Platform.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

1. A retrospective study assessing the acceleration effect of type I Helicobacter pylori infection on the progress of atrophic gastritis.Scientific reports · 2021
   Article
2. Epitope peptides of Helicobacter pylori CagA antibodies from sera by whole-peptide mapping.Journal of gastroenterology · 2019
   Article
3. Current understanding and management ofF1000Research · 2018
   Review
4. Diagnostic Value of the Pylori DuoTect Test for Helicobacter pylori Detection in the Vietnamese Population.Helicobacter
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

11 authors at 4 institutions in 3 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as